Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence
TGF-β activity is a dominant feature of intermediate- to unfavorable-risk prostate tumors prone to biochemical failure after EBRT with ADT and may serve as an independent prognostic biomarker beyond existing clinical criteria.
Authors
- Shana Y. Trostel (ORCID: https://orcid.org/0000-0002-5929-2576)
- William A. Hall (ORCID: https://orcid.org/0000-0001-7017-6755)
- Kenneth L. Zeitzer (ORCID: https://orcid.org/0009-0004-5744-9025)
- Elai Davicioni (ORCID: https://orcid.org/0000-0001-9136-099X)
- Radka Stoyanova (ORCID: https://orcid.org/0000-0002-1301-3228)
- Barış Türkbey (ORCID: https://orcid.org/0000-0003-0853-6494)
- Anson T. Ku (ORCID: https://orcid.org/0000-0002-6471-5502)
- Bradford J. Wood (ORCID: https://orcid.org/0000-0002-4297-0051)
- Peter A. Pinto (ORCID: https://orcid.org/0000-0002-0190-5931)
- Adam G. Sowalsky (ORCID: https://orcid.org/0000-0003-2760-1853)
- Howard M. Sandler (ORCID: https://orcid.org/0000-0002-8193-5769)
- Hyunnam Ryu (ORCID: https://orcid.org/0000-0002-8408-703X)
- Boon Hao Hong (ORCID: https://orcid.org/0000-0002-2822-7480)
- Lucas C. Mendez (ORCID: https://orcid.org/0000-0002-0440-3320)
- Stephanie A. Harmon (ORCID: https://orcid.org/0000-0002-2507-2399)
- Anand B. Desai (ORCID: https://orcid.org/0009-0003-9114-1246)
- Alan Pollack (ORCID: https://orcid.org/0000-0002-1801-2865)
- Houssein Abdul Sater (ORCID: https://orcid.org/0000-0003-1975-3726)
- Deborah E. Citrin (ORCID: https://orcid.org/0000-0002-4391-2734)
- Melvin L.K. Chua (ORCID: https://orcid.org/0000-0002-1648-1473)
- Peter L. Choyke (ORCID: https://orcid.org/0000-0003-1086-8826)
- Uma Shankavaram (ORCID: https://orcid.org/0000-0001-9659-0284)
- Mack Roach (ORCID: https://orcid.org/0000-0002-3546-8565)
- Sumeyra Kartal (ORCID: https://orcid.org/0000-0002-6728-7080)
- Yang Liu (ORCID: https://orcid.org/0009-0007-1986-7025)
- Hong Zhang (ORCID: https://orcid.org/0000-0001-7316-0214)
- Nicole V. Carrabba (ORCID: https://orcid.org/0000-0003-4118-9690)
- James A. Proudfoot (ORCID: https://orcid.org/0009-0008-7063-5761)
- Nirav S. Kapadia (ORCID: https://orcid.org/0000-0001-7230-5784)
- Stephanie L. Pugh (ORCID: https://orcid.org/0000-0002-5977-8912)
Institutions
- Leidos (United States) (US)
- Cedars-Sinai Medical Center (US)
- National Institutes of Health (US)
- University of Miami (US)
- University of California, San Francisco (US)
- Lund University (SE)
- Medical College of Wisconsin (US)
- Thomas Jefferson University Hospital (US)
- Summa Akron City Hospital (US)
- London Health Sciences Centre (CA)
- American College of Physicians (US)
- Occupational Cancer Research Centre (CA)
- University of Miami Hospital (US)
- Dartmouth Psychiatric Research Center (US)
- Veracyte (United States) (US)
- National Cancer Centre Singapore (SG)
- National Cancer Institute (US)
- ABS Consulting (United States) (US)
- Jefferson Hospital (US)
- National Institutes of Health Clinical Center (US)
- NRG Oncology (US)
- Dartmouth Health (US)
- Leidos Biomedical Research Inc. (United States)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2186
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Prostate Cancer Foundation
- AstraZeneca
- Nvidia
- Dartmouth College
- Association of Canadian Universities for Research in Astronomy
- London Health Sciences Centre
- Academic Medical Organization of Southwestern Ontario
- Elekta
- National Comprehensive Cancer Network
- BeiGene
- NRG Oncology
- Veracyte
- Seagen
- National Institutes of Health
- National Cancer Institute
- National Institute of Biomedical Imaging and Bioengineering
- Moonshot Research and Development Program
- Cancer Moonshot